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APC- Antigen presenting cell




IFN-γ- Interferon Gamma 
TNF-β- Tumor Necrosis Factor Beta
Introduction and Background
The National Vital Statistics Reports presented data from a 
study conducted regarding the total number of births regis-
tered in the United States, in 2015. The results showed that 
there were 3,978,497 births recorded, only 1% less than the 
total number of births registered in 2014 (Martin, et al. 2017). 
Many women, worldwide, have successfully given birth to babies, 
which interests researchers in the field of immunology. During a 
lecture in England, in 1953, a British immunologist named Peter 
Medawar asked, “how does the pregnant mother contrive to 
nourish within itself, for many weeks or months, a fetus that is 
an antigenically foreign body (Betz, 2010)?” Since then, research-
ers have been asking the same question (Anonymous, 1999)?
Methods
The research discussed in this paper was compiled from various 
published articles, taken from Touro’s database, including Proquest 
Science, EBSCO, and PubMed to research why a mother does not 
reject a genetically different fetus growing inside of her.
Discussion 
A. The immune system targets foreign objects
The human body’s immune system is a complex network of 
biological structures intricately designed to protect the body 
against foreign objects. Foreign objects may be anything the 
body does not recognize as self, which may include, bacteria, 
viruses, parasites, and tumors. When a foreign object enters the 
body, there is a cascade of events carried out by the body’s 
immune system. First, the body must identify the foreign object 
as “non-self”, destroy the pathogen, and lastly, create memory 
cells to ensure that the foreign object does not attack again 
(Gilley,  et all. 2009).
1.Recognizing “non- self” Objects
One of the main roles of the immune system is to recognize a 
pathogen and induce a response to eradicate it. Immune system 
cells such as white blood cells or leukocytes aid in carrying out 
the tasks. In order to initiate any immune response, an antigen 
(Ag) must be recognized by special receptors. T-Lymphocytes, 
killer T cells and helper T cells, play a crucial role in the recog-
nition of Ag. T-cells recognize foreign Ag by the presentation of 
peptides by the major histocompatibility complex (MHC). The 
two classes of MHC are MHC I and MHC II. Major histocompat-
ibility complex class I generally presents an intracellular viral  Ag 
to cells that contain CD8+ proteins. These Ag will be destroyed 
by Cytotoxic T-Lymphocytes, while MHC Class II generally 
presents extracellular bacterial Ag to cells that contain CD4+ 
proteins. These Ag are recognized by Helper T-Lymphocytes and 
will be destroyed with the help of Ab. (Joyce, 2001). CD8+ and 
CD4+ are cell surface molecules that bind to their respective 
MHC on an antigen-presenting cell (APC). One of the most 
common cells that act as an APC are macrophages. (Miceli, 
Parnes, 1991).
2.Destroying a Pathogen
After the body recognized a pathogen as “non-self,” the immune 
system will try to rid the body of the foreign object. There are 
two main types of pathogens that will elicit two different re-
sponses. The first type is when bacteria enter the human body; 
helper T cells will release certain cytokines and chemokines. 
These are certain chemicals that act as chemoattractants for 
other leukocytes to aid in an inflammatory response. Secondly, 
will produce Plasma cells, a derivative of lymphocytes, make an-
tibodies (Ab) that will help destroy the pathogen. Antibodies 
are a Y shape structure, consisting of glycoproteins called immu-
noglobulins (Ig). There are 5 main isotypes of Ig with different 
roles, which include: IgG, IgE, IgM, IgA, IgD. Each Ab will bind to a 
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specific antigen, comparable to the interaction with a lock and a 
key (Author Unknown, 2016).
In order to help T cells produce Ab, B- lymphocytes will pro-
duce specific Ab to help destroy pathogens. Antibodies produced 
by B cells will circulate the body via the bloodstream and can 
bind to foreign objects. After a B-cell recognizes a pathogen, the 
cell matures into a plasma cell, which produces large quantities 
of Ab. Antibodies have 3 main functions in the immune system. 
The first role is neutralization, which is when an Ab binds to the 
surface of the pathogen, thus denying any entry into the normal 
body cells. The second role is to activate other defense cells 
that are in the body that can elicit an inflammatory response, for 
example, phagocytes. The third role is to activate a complement 
system, which attracts defense cells to the infection site and 
destroys the pathogen (Author Unknown, 2016). 
The second type of pathogen that will cause an immune re-
sponse is infection with a virus. In this case, activated Cytotoxic 
T- cells are able to directly destroy the pathogen when it dis-
plays pathogen peptides on the MHC Class 1. Cytotoxic- T cells, 
also called Killer T cells release cytotoxins, such as perforin, 
which creates a hole in the wall of the infected cell. This in turn 
kills the cell along with the pathogen due to the loss of fluid 
(Author Unknown, 2016)
B. Fetal Cells and a Mother’s Immune System
In order to better explain the interaction between fetal cells 
and the mother’s immune system, one must understand what 
happens after a sperm fertilizes an egg. Once an egg is fertilized, 
it rapidly divides to form the blastocyst, a hollow ball of cells 
comprised of two portions. One is the inner cell mass that will 
become the embryo, which will develop into a fetus about eight 
weeks after conception. The second is the outer layer of the 
blastocyst, which will become the trophoblast. The trophoblast 
will ultimately occupy the lining of the uterus, thus facilitating 
embryonic implantation (Urman, Balaban 2001).
C. Immune System During Pregnancy
Based on the roles of the human’s immune system, one could 
assume that a mother’s immune system would try to eliminate 
a fetus. When a mother conceives a child, genetic material from 
both the mother and the father are incorporated into the fetus, 
however the mother’s mother’s side of the placenta is genetical-
ly different from the fetus. Therefore, the fetus inside the womb 
would be considered “non-self” (Lightner, et al, 2008). Peter B. 
Medawar suggested the “immunological paradox of pregnancy” 
(Mor,  2007). He proposed that since the fetus is considered 
“semiforeign,” there must be a conflict between the fetus and 
the mother’s immune system. For over 60 years since Medawar 
posed this phenomenon, there have been many attempts to 




The first hypothesis explains that the fetal tissue is unrecogniz-
able as “nonself” by the mother’s immune cells due to a mechan-
ical barrier (Mor, 2007). The uterus of a pregnant mother has a 
mechanical barrier, consisting of synctiotrophoblasts that envelop 
the fetus. This trophoblast-immune interaction includes three 
stages (Fig. 1). During the first stage of attraction, the trophoblast 
cells secrete chemoattractants that will signal immune cells to 
migrate to the implantation site. The implantation site refers to 
the area of the uterus in which the trophoblasts invade.  After 
attraction, the trophoblasts produce cytokines that regulate the 
differentiation of immune cells. This stage is called recruitment 
and/or education. Upon completion of these two steps, the re-
sponse can take place. In this stage, the immune cells from stage 
two respond to different signals (Swain, 2013). After completion 
of all three stages, the mechanical barrier is formed. This in turn 
prevents the movement of activated T cells from the periphery 
to the implantation site and enables antigens that are inside the 
barrier to be undetected by the mother’s immune system.
b. Suppressed Immune System During Pregnancy
Research done by David Munn and his colleagues at the Medical 
College of Georgia in Augusta suggests a different hypothesis. 
They discovered that macrophages, an important immune cell 
involved in antigen presentation, can disable killer T-cells. This 
in turn will prevent the T cells from attacking any object that is 
recognized as non-self (Anonymous, 1999). In order for this to 
occur, the synctiotrophoblasts in the placenta produces an en-
zyme known as indoleamine 2,3-dioxy-genase (IDO). The func-
tion of IDO is to destroy tryptophan, an amino acid required 
by T cells to destroy a foreign object. In 1990, Andrew Mellor, a 
colleague of Munn, concluded that IDO inhibits a mother’s T cell 
response towards a genetically different fetus. On the contrary, 
if a mother fails to produce IDO, it would  cause the mother to 
miscarry (Gura, 1998).
Munn and his colleagues conducted experiments in to prove 
their hypothesis. They used two groups of pregnant mice; one 
group had been bred to genetically identical fathers of the same 
strain while the second group was bred to fathers from a ge-
netically different strain (Gura,  1998). The experimenters then 
embedded time release-capsules consisting of either 1-meth-
yl-tryptophan, which is an IDO inhibitor, or a control substance 
underneath the skin of the pregnant mice. Results showed that 
only the mice carrying genetically different fetuses that had 
been given the inhibitor rejected their fetuses (Anonymous, 
1999) (Gura 1998).  Interestingly, the embryos developed nor-
mally until inflammatory cells migrated to the implantation site 
and caused hemorrhaging around the embryo. Munn proposed 
“the mother is rejecting the placenta and eventually the em-
bryo chokes off and dies” (Gura, 1998). From the data collected, 
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Munn and his colleagues concluded that after implantation, an 
embryo starts making connections with the mother’s blood 
supply. Sequentially, synctiotrophoblasts will start producing 
IDO, destroying tryptophan and suppressing the maternal im-
mune system (Gura, 1998). However, other researchers have 
reservations about this hypothesis. In Pregnancy Reconceived, 
Mor argues that if the maternal immune system is suppressed, it 
would be nearly impossible for a mother and its fetus to survive. 
Exposure to any pathogen would be fatal (Mor, 2007). 
c. Local Active Suppression in Decidua
In addition to the general suppression of a mother’s immune 
system, researchers have found that an important role in the 
maternofetal interaction is the local active suppression by cells 
in the decidua (Chaouat,  1990). The decidua is a mucous mem-
brane lining of the uterus during pregnancy. This lining allows 
for nutrition and gas exchange before the placenta is functional 
(Mizugishi, et al. 2007).  Cells located in the decidua may inhibit 
the production of lymphocytes thus leading to the inhibition of 
the production and expression of receptors for interleukin 2 (IL-
2). IL-2 is a cytokine signaling molecule produced by activated T 
cells and is crucial for the rejection of foreign objects in the body. 
This type of suppressor cell is trophoblast independent. However, 
there is another type of cell that suppresses the role of IL-2 in 
the maternal immune system and these suppressor cells in the 
decidua are trophoblast dependent. ¬ Both types of suppressor 
cells have an effect on the production or action of IL-2. 
Therefore, local active suppression aids in the prevention of 
foreign objects attacking the mother’s immune system and fetal 
rejection (Chaouat,  1990.)
d. Cytokine-shift Hypothesis
This hypothesis suggests that during pregnancy, the balance 
of cytokines within the mother’s body shifts. This cytokine 
shift causes immunological changes in the maternal immune 
response (Mor, 2007). Cytokines, which are important in cell 
signaling,  are released by Th1 and Th2 helper cells. However, 
each subgroup facilitates a different immune response. Th1 cells 
secrete IL-2, Interferon gamma (IFN-γ), and Tumor necrosis 
factor, Beta (TNF-β) causing a cell mediated immune response, 
while Th2 cells secrete IL-4, 5, 6, 10, and 13. These are mainly in-
volved in antibody production (Rincón et.al, 1997). Additionally, 
IL secreted by Th2 cells simulate a humoral immunity and aids 
in the inhibition of the production of TNF-β and IFN-γ (Kidd 
2003). The production of IFN-γ, TNF-β and IL-2 are believed to 
be damaging to pregnancy. In an experiment studying pregnant 
mice, these cytokines were injected into the mice and caused 
fetal loss (Koch and Platt, 2003). Previous research suggests that 
there is a shift towards a higher production of cytokines re-
leased by Th2 during pregnancy and a diminished production of 
Th1 cytokines (Hoshimoto,et al. 2000). 
When a foreign object enters the body of a women who is 
not pregnant, Th1 cells will secrete pro inflammatory cytokines 
that will signal for a cell mediated response to occur. However, 
according to the cytokine-shift hypothesis, the balance of Th1 
and Th2 will go towards the secretion of cytokines by Th2, re-
sulting in a suppressed inflammatory response (Mor,  2007).) 
Many studies have been conducted in an effort to better un-
derstand the shift of Th1 to Th2 cytokine secretion during 
pregnancy. In an experiment conducted by Hoshimoto,  et. al. 
(2009), they gathered thirty female subjects. Group A consisted 
of ten women who were non-pregnant women with regular 
menstrual cycles and the other 20 healthy and pregnant women. 
The pregnant women were separated into two groups, B and 
C according to weeks of gestation. Group B consisted of 10 
pregnant women who were in their first trimester and group C 
consisted of 10 women in their third trimester. The experiment-
ers took samples of peripheral venous blood and separated the 
plasma at -80°C until ready for analysis. The results of the ex-
periment showed the correlation between the plasma levels of 
sCD26 and sCD30 and pregnancy. sCD26 and sCD30 are mol-
ecules on the surface of activated Th1 and Th2 cells, respectively. 
Therefore, plasma levels of sCD26 and sCD30 correlate to Th1 
and Th2 responses, respectively. 
sCD26 concentrations among group A were significantly 
higher than group B. Furthermore, the concentration of group 
B was significantly higher than group C. This indicates that the 
highest concentration of Th1 cells were among those who 
were not pregnant, and the lowest concentration was among 
the pregnant women in their third trimester. Concentrations of 
sCD30 among groups A and B did not significantly vary, howev-
er, compared to the concentration level of group C, they were 
significantly higher. The researchers concluded that there was a 
significant decrease in sCD26 levels among pregnant mothers 
possibly due to the shift from Th1 cytokine secretion. However, 
sCD30 levels did not differ between non-pregnant women and 
women in their first trimester, but decreased among women 
in their third trimester. This decrease may be explained by 
the increase in water retention as pregnancy progresses. 
Furthermore, the researchers advise for additional investigation 
in order to validate the cytokine-shift hypothesis. 
Many researchers agree that cytokines play a crucial 
role during pregnancy. As explained in the research done by 
Hoshimoto et.al, Koch and Platt mutually agree that a Th2 
response is necessary for the fetus to survive in the womb. 
Results from an experiment with mice showed that there was 
a 20-50% rate of fetal loss due to a lack of Th2 cytokine pro-
duction. Furthermore, they applied this idea to humans and sug-
gest that irregularities with Th2 cytokine response may lead to 
miscarriages. The mechanism that causes the shift between Th1 
and Th2 cytokine response in pregnancy is unknown. However, 
Koch and Platt propose two plausible possibilities. Firstly, there 
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is a prevention of Th1 cytokine secretion that allows the Th2 
response to take over or secondly; there is a specific Th2 re-
sponse, which inhibits the Th1 response (Koch, Platt, 2003).
Conclusion
This paper attempted to explain the reasons why a mother 
does not reject her genetically different fetus. Although it was 
not until the 1950’s when Professor Medawar first posed this 
question, the wealth of knowledge on this topic is rapidly ex-
panding. However, despite the few flaws with the hypotheses, 
additional research is being studied to resolve the issue.
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